Provider review, September 2026
R2 publishes a regulatory-status and evidence-strength table against its own catalogue, and tells readers in that table that the human evidence for some of what it sells is insufficient.
R2 Medical Clinic does not publish a price today.
R2 Medical Clinic also sells 11 compounds this site boards without publishing a price for them: Sermorelin, Ipamorelin (board ranks no provider), Tesamorelin, NAD+, BPC-157 (board ranks no provider), TB-500 (board ranks no provider), PT-141, GHK-Cu, MOTS-C (board ranks no provider), KPV (board ranks no provider) and Epitalon (board ranks no provider).
R2 Medical Clinic is not a paid partner; this link may earn a commission if that changes. Full disclosure.
The table has four columns: the peptide, its primary mechanism of action, its regulatory status and the strength of the human clinical evidence. Every compound the clinic offers gets a row.
For the visceral-fat peptide the regulatory column names the approved indication and then says plainly that it is not approved for general weight loss or anti-aging — a distinction most sellers of that compound blur.
For the growth-hormone peptide it says there is historical approval and no currently marketed approved product, which is precise and correct and rarely stated.
For the tissue-repair peptide the evidence column says the research is predominantly animal and laboratory work and that the clinical evidence is insufficient to establish efficacy or safety in humans. That is a seller writing the case against its own product, in a table, on the page selling it.
That last sentence contains the words a research-use-only classifier looks for, and firing on it would file a licensed clinic as a research-chemical vendor.
It is the inverse of what such a pattern is looking for: a clinical seller disclosing weak evidence, not a laboratory supplier disclaiming human use.
This is one of several sellers in this batch on which the same inversion happens. Every one was read in full before a category was assigned.
The joined text of the service page and the terms contains no dollar amount at all. Eleven compounds this site tracks are named and none carries a figure.
No corporate entity is published; the footer names three locations in one state. No dispensing pharmacy is named and no state coverage list exists.
One instrument note about this host: its not-found page is nearly twice the size of its real terms page, so nothing here can be judged by weight and only the status code separates a real page from a missing one.
Trellis Vitality frames its program around body-composition tracking rather than scale weight, pairing NAD+, glutathione and tesamorelin with at-home biomarker panels and a 90-day re-test, and names its dispensing pharmacy, VialsRX in Houston, by address.
Read the full Trellis Vitality review
Trellis Vitality is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Trellis VitalityIt publishes a table giving each compound's regulatory status and the strength of its human clinical evidence, and grades some of its own catalogue as insufficient.
No. A research-use pattern fires on its evidence column, which is a licensed clinic disclosing weak evidence rather than a supplier disclaiming human use.
No. Neither page read carries a dollar amount.
No corporate entity appears; the footer names three locations in one state.
Eleven that this site tracks are named on the service page.
R2 Medical Clinic is not a paid partner; this link may earn a commission if that changes. Full disclosure.